IN2014KN01037A - Methods and compositions for the treatment of diabetes and related symptoms - Google Patents
Methods and compositions for the treatment of diabetes and related symptomsInfo
- Publication number
- IN2014KN01037A IN2014KN01037A IN1037/KOLNP/2014A IN1037KON2014A IN2014KN01037A IN 2014KN01037 A IN2014KN01037 A IN 2014KN01037A IN 1037KON2014 A IN1037KON2014 A IN 1037KON2014A IN 2014KN01037 A IN2014KN01037 A IN 2014KN01037A
- Authority
- IN
- India
- Prior art keywords
- diabetes
- compositions
- treatment
- related symptoms
- glutamine
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 4
- 208000024891 symptom Diseases 0.000 title abstract 3
- 230000037396 body weight Effects 0.000 abstract 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 abstract 2
- 150000002308 glutamine derivatives Chemical class 0.000 abstract 1
- 150000002309 glutamines Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention is directed to methods and compositions for the treatment of diabetes and related symptoms. It is more specifically directed to compositions including L glutamine its salts or its derivatives and uses of such compositions in the treatment of diabetes and related symptoms. In a method aspect the present invention provides a method of treating diabetes. The method involves ingesting 0.05 g/kg body weight to 10.0 g/kg body weight of L glutamine an L glutamine salt or an L glutamine derivative per day by a person who has diabetes.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161629633P | 2011-11-21 | 2011-11-21 | |
| PCT/US2012/000557 WO2013077893A1 (en) | 2011-11-21 | 2012-11-17 | Methods and compositions for the treatment of diabetes and related symptoms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014KN01037A true IN2014KN01037A (en) | 2015-10-09 |
Family
ID=48470183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1037/KOLNP/2014A IN2014KN01037A (en) | 2011-11-21 | 2014-05-15 | Methods and compositions for the treatment of diabetes and related symptoms |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20130143968A1 (en) |
| EP (2) | EP3437649A1 (en) |
| JP (4) | JP6089042B2 (en) |
| CN (3) | CN108354916A (en) |
| BR (1) | BR112014011898A2 (en) |
| ES (1) | ES2785094T3 (en) |
| HK (1) | HK1257401A1 (en) |
| IN (1) | IN2014KN01037A (en) |
| PH (2) | PH12014501052B1 (en) |
| WO (1) | WO2013077893A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190146A1 (en) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | Amino acid compositions and methods for the treatment of liver diseases |
| US10682325B2 (en) | 2017-08-14 | 2020-06-16 | Axcella Health Inc. | Compositions and methods for the treatment of liver diseases and disorders associated with one or both of hyperammonemia or muscle wasting |
| JP2021527670A (en) | 2018-06-20 | 2021-10-14 | アクセラ・ヘルス・インコーポレイテッドＡｘｃｅｌｌａ Ｈｅａｌｔｈ Ｉｎｃ． | Compositions and methods for the treatment of fat infiltration in muscle |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6031000A (en) * | 1998-06-23 | 2000-02-29 | Iowa State University Research Foundation, Inc. | Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use |
| EP1399471B1 (en) * | 2001-06-27 | 2008-01-30 | Probiodrug AG | Use of dipeptidyl peptidase iv inhibitors as therapeutics for neurological disorders |
| SE0201713D0 (en) * | 2001-11-23 | 2002-06-06 | Gramineer Internat Ab | New methods and use III |
| TWI351278B (en) * | 2002-03-01 | 2011-11-01 | Nisshin Pharma Inc | Agent for preventing and treating of liver disease |
| US20070025953A1 (en) * | 2005-07-27 | 2007-02-01 | Jones Michael R | Co-therapy for diabetic conditions |
| CA2774197A1 (en) * | 2006-04-22 | 2008-04-03 | Harbor Biosciences, Inc. | Drugs and uses to modulate inflammation, metabolic disorders and other conditions |
| EP2077110A4 (en) * | 2006-09-29 | 2012-06-27 | Ajinomoto Kk | COMPOSITION CONTAINING GLUTAMINE FOR INCREASING BLOOD FLOW |
| US20080221074A1 (en) * | 2006-11-17 | 2008-09-11 | Jaime Flores-Riveros | Drug Screen and Treatment Method |
| EP2057905A1 (en) * | 2007-11-12 | 2009-05-13 | TIMA Foundation | Composition for moderating Triglyceride and Cholesterol Levels |
| LT2376077T (en) * | 2009-01-12 | 2017-08-10 | Biokier Inc. | Composition and method for treatment of diabetes |
| NL1036746C2 (en) * | 2009-03-20 | 2010-09-21 | Glnp Holding B.V. | KIT OF PARTS CONTAINING L-GLUTAMINE AND EGCG. |
| CA2774616A1 (en) * | 2009-09-23 | 2011-03-31 | Biokier, Inc. | Composition and method for treatment of diabetes |
-
2012
- 2012-11-17 ES ES12850971T patent/ES2785094T3/en active Active
- 2012-11-17 CN CN201810134012.1A patent/CN108354916A/en active Pending
- 2012-11-17 CN CN201280056939.9A patent/CN103945858A/en active Pending
- 2012-11-17 US US13/694,301 patent/US20130143968A1/en not_active Abandoned
- 2012-11-17 EP EP18196395.0A patent/EP3437649A1/en not_active Withdrawn
- 2012-11-17 PH PH1/2014/501052A patent/PH12014501052B1/en unknown
- 2012-11-17 JP JP2014542296A patent/JP6089042B2/en not_active Expired - Fee Related
- 2012-11-17 WO PCT/US2012/000557 patent/WO2013077893A1/en not_active Ceased
- 2012-11-17 EP EP12850971.8A patent/EP2782588B1/en not_active Revoked
- 2012-11-17 PH PH1/2020/550726A patent/PH12020550726B1/en unknown
- 2012-11-17 CN CN201810135122.XA patent/CN108478551A/en active Pending
- 2012-11-17 BR BR112014011898A patent/BR112014011898A2/en not_active IP Right Cessation
-
2014
- 2014-05-15 IN IN1037/KOLNP/2014A patent/IN2014KN01037A/en unknown
-
2016
- 2016-10-24 JP JP2016207931A patent/JP6389495B2/en not_active Expired - Fee Related
-
2018
- 2018-03-08 JP JP2018041934A patent/JP6550160B2/en not_active Expired - Fee Related
- 2018-08-17 JP JP2018153440A patent/JP2018199692A/en active Pending
- 2018-12-26 HK HK18116609.9A patent/HK1257401A1/en unknown
-
2019
- 2019-01-15 US US16/350,812 patent/US20190192463A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2782588A4 (en) | 2015-05-20 |
| EP2782588A1 (en) | 2014-10-01 |
| PH12014501052A1 (en) | 2014-06-30 |
| EP2782588B1 (en) | 2020-04-15 |
| CN103945858A (en) | 2014-07-23 |
| EP3437649A1 (en) | 2019-02-06 |
| PH12020550726B1 (en) | 2022-11-09 |
| PH12020550726A1 (en) | 2021-06-14 |
| CN108354916A (en) | 2018-08-03 |
| JP2018115175A (en) | 2018-07-26 |
| WO2013077893A1 (en) | 2013-05-30 |
| HK1257401A1 (en) | 2019-10-18 |
| BR112014011898A2 (en) | 2017-05-16 |
| US20190192463A1 (en) | 2019-06-27 |
| JP2018199692A (en) | 2018-12-20 |
| US20130143968A1 (en) | 2013-06-06 |
| ES2785094T3 (en) | 2020-10-05 |
| JP6389495B2 (en) | 2018-09-12 |
| PH12014501052B1 (en) | 2020-10-09 |
| JP2017052766A (en) | 2017-03-16 |
| JP6089042B2 (en) | 2017-03-01 |
| JP6550160B2 (en) | 2019-07-24 |
| CN108478551A (en) | 2018-09-04 |
| JP2014533689A (en) | 2014-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2010080756A3 (en) | Harmine derivatives for reducing body weight | |
| MX351464B (en) | Methods for the treatment of allergic diseases. | |
| MY173877A (en) | Branched 3-phenylpropionic acid derivatives and the use thereof | |
| TN2014000122A1 (en) | 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases | |
| EA201590371A1 (en) | 1,4-DESIGNED PYRIDAZIN ANALOGUES AND METHODS OF TREATMENT RELATED TO SMN DEFICIENCY CONDITIONS | |
| IN2014CN00562A (en) | ||
| MX2013011691A (en) | Inhibitors of viral replication, their process of preparation and their therapeutical uses. | |
| MX360634B (en) | Substituted 3-haloallylamine inhibitors of ssao and uses thereof. | |
| MX2015007916A (en) | Peri-carbinols. | |
| UA110983C2 (en) | 1,2,3,4-TETRAHYDROCHINOLINE DERIVATIVE SUITABLE FOR THE TREATMENT OF DIABETES | |
| MX2015009444A (en) | Novel traps in the treatment of macular degeneration. | |
| SG10201810401RA (en) | Pharmaceutical combinations for treating cancer | |
| IN2015DN01151A (en) | ||
| PH12015502302A1 (en) | Treatment of allergic rhinitis using a combination of mometasone and olopatadine | |
| SG10201900541QA (en) | Derivatives of xanthone compounds | |
| FI20115165A0 (en) | Therapeutic and diagnostic methods | |
| IN2014KN01255A (en) | Methods and compositions for the treatment of diverticulosis | |
| MX2013002208A (en) | Sulfonylpiperazine derivatives that interact with glucokinase regulatory protein for the treatment of diabetes. | |
| IN2014KN01037A (en) | Methods and compositions for the treatment of diabetes and related symptoms | |
| NZ707773A (en) | Methods of treating liver diseases | |
| IN2014DN08443A (en) | ||
| IN2014CN02315A (en) | ||
| UA113859C2 (en) | SPIROTIENOPIRAN-PIPERIDINE DERIVATIVES AS AN ORL-1 RECEIVER ANTAGONS FOR THEIR APPLICATION IN THE TREATMENT OF ALCOHOLIC DEPENDENCE AND ABUSE | |
| IN2014DN00123A (en) | ||
| PH12012501476A1 (en) | Aminoquinoline derivatives |